Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer.
Ayako ShionoHisao ImaiSatoshi WasamotoTakeshi TsudaYoshiaki NagaiHiroyuki MinemuraYutaka YamadaTakayuki KishikawaYukihiro UmedaHiroki TakechiOu YamaguchiAtsuto MouriKyoichi KairaHirokazu TaniguchiKoichi MinatoHiroshi KagamuPublished in: Cancer medicine (2022)
Despite hematologic toxicities, especially decreased neutrophil count, atezolizumab, carboplatin, and etoposide combination chemotherapy demonstrates favorable effectiveness and acceptable toxicity in elderly patients. Thus, atezolizumab plus carboplatin and etoposide could be the preferred standard treatment modality for elderly patients with ED-SCLC.
Keyphrases
- phase ii study
- small cell lung cancer
- locally advanced
- middle aged
- phase iii
- emergency department
- community dwelling
- systematic review
- oxidative stress
- open label
- electronic health record
- big data
- peripheral blood
- rectal cancer
- clinical trial
- combination therapy
- artificial intelligence
- deep learning
- replacement therapy
- data analysis
- chemotherapy induced